Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-02-11 Interim / Quarterly Rep…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AZN: FULL-YEAR 2020 RESULTS
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, reporting full-year 2020 financial results. It includes detailed financial data such as total revenue, product sales, earnings per share, segment performance, and guidance for the next fiscal year. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year is not applicable here since this is a full-year report. The document is not an announcement of a report but contains substantive financial data and management commentary. Form 6-K is used by foreign private issuers to report material information, often including interim or annual results. Given the detailed financial results and the nature of the filing, this corresponds to an Interim / Quarterly Report (IR) type filing, as it is a periodic report with substantive financial data but not a full Annual Report (10-K) or equivalent. Therefore, the best classification is Interim / Quarterly Report (IR).
2021-02-11 English
AstraZeneca Non-Executive Board changes
Board/Management Information Classification · 98% confidence The document is an RNS announcement dated February 11, 2021, titled 'AstraZeneca Non-Executive Board Changes'. It details the intended retirement of two Non-Executive Directors (Geneviève Berger and Graham Chipchase) from the Board following the Annual General Meeting (AGM) on April 30, 2021, and announces subsequent changes to board roles and committee memberships effective March 1, 2021. This content directly relates to changes in the company's board of directors and senior management structure. This aligns perfectly with the definition for Board/Management Information (MANG). Although it mentions the AGM, the primary focus is the director changes, not AGM materials or voting results.
2021-02-11 English
AZN: full-year 2020 results
Earnings Release Classification · 100% confidence The document text explicitly states 'Full-year 2020 results' and provides comprehensive financial tables, including Total Revenue, Product Sales, EPS figures, and guidance for the upcoming fiscal year (FY 2021). It covers the entire fiscal year (FY 2020) performance. This structure and content strongly indicate an official annual financial report. Although it is presented via an RNS mechanism (as suggested by the header 'National Storage Mechanism | Additional information RNS Number : 6947O'), the document itself is the detailed annual results disclosure, not just an announcement of the report's publication. Therefore, it aligns best with the Annual Report (10-K) definition, which covers 'company activity and full financial performance' for the year. Given the context of a major listed company reporting full-year results, 10-K is the most appropriate classification, even if the immediate delivery mechanism is an RNS filing. FY 2020
2021-02-11 English
425 Filing
Investor Presentation Classification · 95% confidence The document is a detailed presentation by AstraZeneca PLC dated February 11, 2021, related to FY2020 results. It includes forward-looking statements, financial highlights such as revenue growth, earnings per share, pipeline updates, and strategic information about the acquisition of Alexion Pharmaceuticals. The text references a conference call and webcast for investors and analysts, and contains detailed financial and operational data, including revenue breakdowns, product pipeline status, and market performance. The presence of slides with agenda, speaker list, and detailed financial and strategic content indicates this is a presentation aimed at investors. It is not a full annual report (10-K), nor a regulatory filing or proxy statement. It is not a transcript of a call but rather the presentation materials used during the call. Therefore, the document best fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-02-11 English
425 Filing
Management Reports Classification · 95% confidence The document is a transcript of a video message from AstraZeneca's CEO discussing the company's 2020 performance, including revenue growth, product sales, and the proposed acquisition of Alexion Pharmaceuticals. It includes forward-looking statements and detailed business updates but does not contain formal financial statements or comprehensive financial data typical of an annual or interim report. The document also references the upcoming filing of a proxy statement/prospectus related to the acquisition, indicating this is part of merger-related communications. The presence of detailed business and financial performance commentary, along with strategic outlook and acquisition discussion, aligns with a Management Discussion and Analysis (MDA) type document rather than a full Annual Report or Earnings Release. It is not a regulatory filing, proxy solicitation, or announcement of a report publication. Therefore, the best fit is Management Reports (MDA).
2021-02-11 English
425 Filing
Annual Report Classification · 95% confidence The document is a media briefing pack filed by AstraZeneca PLC pursuant to Rule 425 under the US Securities Act of 1933. It includes detailed financial results for the full year 2020, including revenue, product sales, operating profit, EPS, and guidance for 2021. It also discusses the proposed acquisition of Alexion Pharmaceuticals, including regulatory filings and proxy statements related to the transaction. The document contains substantive financial data and analysis, including detailed financial performance metrics and forward-looking statements. It is not merely an announcement of a report or a certification. The presence of detailed financial results and strategic information indicates this is a comprehensive financial report for the full fiscal year. Therefore, the document is best classified as an Annual Report (10-K equivalent) or a full-year results report. Given the US context and the detailed financial data, the best fit is Annual Report (10-K).
2021-02-11 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.